A. Introduction --;I. Enterogastrone Concept --;II. Incretin Concept --;III. Evidence for the Existence of GIP --;B. Chemistry --;I. Isolation and Purification --;II. Amino Acid Sequence --;III. Correction to Sequence --;IV. Synthesis --;C. Physiological Actions of Exogenous GIP --;I. Gastrointestinal Effects --;II. Metabolic Effects --;D. Radioimmunoassay --;I. Development --;II. Immunordactive GIP (IR-GIP) --;III. Inhibition of IR-GIP Release --;IV. Nature of IR-GIP --;E. Localization --;I. Cellular Localization --;II. Release Studies --;F. Pathophysiology --;I. Diabetes Mellitus --;II. Pancreatitis --;III. Other Gastrointestinal Disorders --;IV. Obesity --;V. Uraemia --;VI. Other Clinical Situations --;G. Summary and Conclusions --;I. Physiological Role --;II. Pathophysiological Role --;References --;Acknowledgements.
Dr. Raymond Pederson, Dr. Jill Dryburgh and I commenced work on GIP in 1968, when, with the generous help of Professor Viktor Mutt and Professor Erik Jorpes of the Karolinska Inst,itute, Stockholm, we were able to establish that there existed an inhibitory material for acid secretion in cholecystokinin-pancreozymin prepara- tions.